Harmony Biosciences
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences announced a leadership change on October 12, 2026. Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
What changed
Peter Anastasiou was named President and Chief Executive Officer. Jeffrey M. Dayno, M.D., will retire as President and CEO at the end of 2026, step down from the Board on December 31, 2026, and serve as a non-executive advisor to the company throughout 2027.
- Leader: Peter Anastasiou
- Role: President and Chief Executive Officer
- Effective: January 1, 2027
- Announcement date: October 12, 2026
Leadership background
Anastasiou is Harmony’s Senior Executive Vice President and Chief Operating Officer and previously served on its Board for three years. He was CEO and a board member of Capsida Biotherapeutics for nearly four years, and earlier was Executive Vice President, a member of the global executive committee, and President of North America at Lundbeck. Earlier roles include management positions at Neuronetics, Bristol-Myers Squibb, and Lilly.
The mandate
Harmony said it remains focused on growing the pitolisant franchise, advancing its CNS pipeline led by BP-205, deploying capital by transacting on value-creating assets, and protecting WAKIX exclusivity. Anastasiou said he looks forward to leading Harmony through its next phase of growth.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Harmony Biosciences leadership announcement.
Related Reports
Onward Energy Appoints Patrick Welch Chief Executive Officer
Onward Energy announced the appointment of Patrick Welch, its CFO since 2023 and Interim President and CEO, as Chief Executive Officer, effective October 27, 2026.
Tully Luxury Travel Names Steven Salm Chief Executive Officer
Tully Luxury Travel named Steven Salm CEO, succeeding founder Mary Jean Tully, who stepped down after nearly four decades and stays on as Brand Ambassador; Salm will lead day-to-day operations and growth.
Harper Names Lelah Manz Chief Executive Officer
Harper appointed former Akamai executive Lelah Manz as CEO, succeeding co-founder Stephen Goldberg.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free